Basilea Pharmaceutica AG Company Description

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.

The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia.

Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials.

Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Basilea Pharmaceutica AG

Country	Switzerland
Founded	2000
Industry	Biotechnology
Sector	Healthcare
Employees	147
CEO	David Veitch

Contact Details

Address: Hegenheimermattweg 167b Allschwil, 4123 Switzerland
Phone	41 61 606 11 11
Website	basilea.com

Stock Details

Ticker Symbol	BSLN
Exchange	SIX Swiss Exchange
Fiscal Year	January - December
Reporting Currency	CHF
ISIN Number	CH0011432447
SIC Code	2836

Key Executives

Name	Position
David Veitch	Chief Executive Officer
Adesh Kaul	Chief Financial Officer
Dr. Gerrit Hauck Ph.D.	Chief Technology Officer
Dr. Laurenz Kellenberger Ph.D.	Chief Scientific Officer
Dr. Marc Engelhardt M.D.	Chief Medical Officer
Dr. Peer Nils Schroder	Head of Corporate Communications and Investor Relations
Damian Heller	General Counsel and Corporate Secretary
Andreas Kumin	Head of Corporate Development
Ursula Eberhardt	Head of Global Human Resources
Mark Jones	Head of Project Management and Preclinical Development